- Report
- October 2024
- 198 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 150 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- May 2024
- 125 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 130 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- August 2024
- 110 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- April 2019
- 73 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- November 2023
- 160 Pages
Global
From €3421EUR$3,599USD£2,874GBP
- Report
- February 2024
- 116 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- February 2024
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 178 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- March 2020
- 121 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- September 2023
- 114 Pages
Global
From €2804EUR$2,950USD£2,356GBP
- Report
- September 2023
- 194 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- June 2022
- 215 Pages
United States
From €2566EUR$2,699USD£2,156GBP
- Report
- January 2020
United States
From €1321EUR$1,390USD£1,110GBP
- Report
- December 2018
- 14 Pages
Global
From €9507EUR$10,000USD£7,986GBP
- Report
- January 2025
- 85 Pages
Global
From €3500EUR$3,944USD£3,043GBP

Prevnar is a vaccine used to protect against pneumococcal disease, a type of bacterial infection that can cause serious illnesses such as pneumonia, meningitis, and sepsis. It is recommended for infants and young children, as well as adults over the age of 65. Prevnar is a conjugate vaccine, meaning it contains a combination of bacterial antigens that stimulate the body's immune system to produce antibodies. The vaccine is administered in a series of four doses, with the first dose given at two months of age.
The Prevnar market is highly competitive, with several major players offering their own versions of the vaccine. These include Pfizer, Merck, GlaxoSmithKline, Sanofi Pasteur, and AstraZeneca. Each company has its own unique formulation of the vaccine, which is designed to provide the best protection against pneumococcal disease. Show Less Read more